Drugs / rDEN2/4delta30(ME)
last change Apr 2006 re-read 3 minutes ago

rDEN2/4delta30(ME)

Vaccine

Developed for
dengue disease
Investigated by
Johns Hopkins Bloomberg School of Public Health · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00094705 Jan 2005 → Apr 2006 dengue disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as rDEN2/4delta30(ME) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00094705 ↗
Modality Vaccine “Live attenuated rDEN2/4delta30(ME) vaccine” NCT00094705 ↗
Route Subcutaneous “One subcutaneous vaccination with a 10\^3 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.” NCT00094705 ↗